Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase NA
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Eligible women will receive neoadjuvant single fraction radiotherapy followed by surgery performed after one year

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Radiation: Single Pre-Operative Radiation Therapy — Ablative preoperative partial breast radiation therapy

Primary Outcomes

  • Incidence of pathological complete response (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-10-08
Completion: 2030-12-31
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maisonneuve-Rosemont Hospital
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Information
Study Contact:
Michael Yassa
514-252-3425
michael.yassa.med@ssss.gouv.qc.ca
Michael Yassa, MD
514-252-3425
Maisonneuve-Rosemont Hospital
Michael Yassa, MD
Maisonneuve-Rosemont Hospital
Interventions
  • Radiation: Radiation: Single Pre-Operative Radiation Therapy — Ablative preoperative partial breast radiation therapy
Study Locations (2 sites)
Maisonneuve-Rosemont Hospital, Montreal, Quebec H1T 2M4 Canada
McGill University Health Center, Montreal, Quebec H4A 3J1 Canada
Eligibility Criteria
Inclusion Criteria: 1. Female aged 50 years or older. 2. Postmenopausal status (Defined as: age 60 OR bilateral ovariectomy OR amenorrhea \> 12 months prior to breast cancer diagnosis without using oral contraceptives/hormone replacement therapy) (65). 3. World Health Organization (WHO) performance status 0-2. 4. Invasive ductal carcinoma proven by biopsy done ≤ 12 weeks from treatment start. 5. Unifocal disease on preoperative staging ultrasound or MRI done ≤ 12 weeks from treatment start. 6. Tumors less than or equal to 2cm clinically on physical exam, as well as on breast ultrasound. 7. No clinical evidence of nodal disease (i.e. cN0), on physical examination done ≤ 12 weeks from treatment start, as well as on breast ultrasound. 8. Estrogen receptor status (ER) positive on biopsy ≥ 80%. 9. Progesterone receptor status (PR) positive on biopsy ≥ 20%. 10. Her2 negative on biopsy. 11. No lymphovascular invasion on biopsy. 12. Low Oncotype DX recurrence score performed on biopsy specimen (RS ≤18). 13. Planned surgery is a partial mastectomy with sentinel lymph node biopsy. Exclusion Criteria: 1. Age less than 50 years. 2. Premenopausal or uncertain menopausal status. 3. A known deleterious mutation in BRCA 1 and/or BRCA 2. 4. Clinical tumor size \> 2.0 cm in greatest diameter on staging ultrasound. 5. Tumor histology limited to lobular carcinoma only. 6. Clinically positive axillary nodes (cN+). 7. Lymphovascular invasion on biopsy. 8. Pure ductal or lobular carcinoma in situ on biopsy. 9. Extensive intraductal component on biopsy. 10. Neoadjuvant hormonal manipulation or chemotherapy. 11. Prior non basal cell or squamous cell skin cancers within 5 years. 12. More than one primary tumor in different quadrants of the same breast. 13. Diffuse microcalcifications on mammography. 14. Paget's disease of the nipple. 15. Previous irradiation to the ipsilateral breast. 16. Presence of an ipsilateral breast implant or pacemaker. 17. Serious non-malignant disease (e.g. cardiovascular, pulmonary, systemic lupus erythematosus (SLE), scleroderma) which would preclude definitive radiation treatment. 18. Estrogen receptor status (ER) not known. 19. Currently pregnant or lactating. 20. Psychiatric or addictive disorders which would preclude obtaining informed consent or adherence to protocol. 21. Geographic inaccessibility for follow-up. 22. Lack of preoperative staging with breast and axillary ultrasound. 23. Inability to adequately plan the patient for the experimental technique. 24. Prior breast cancer.
Conditions Breast Cancer, Melanoma, Gastrointestina...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change from Baseline in ctDNA collected from biospecimens (Through study completion, an average of 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-07-20
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Collaborators: Princess Margaret Hospital, Canada
Principal Investigators:
  • Lillian Siu, MD (PRINCIPAL_INVESTIGATOR) - Princess Margaret Hospital, Canada
  • Philippe Bedard, MD (PRINCIPAL_INVESTIGATOR) - Princess Margaret Hospital, Canada
Contact Information
Study Contact:
Celeste Yu, MSc
416-946-4501
celeste.yu@uhn.ca
Elizabeth Shah
416-946-4501
elizabeth.shah@uhn.ca
Celeste Yu
416-946-4501
celeste.yu@uhn.ca
Princess Margaret Cancer Centre
Interventions
N/A
Study Locations (1 sites)
Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada
Eligibility Criteria
Inclusion Criteria: 1. Patients with histological confirmation of a solid tumor. 2. Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment. 3. Patient must be ≥ 18 years old. 4. All patients must have signed and dated an informed consent form. Exclusion Criteria: None

Taiwan Cancer Moonshot Project

NCT05248763
Recruiting
Conditions Malignant Neoplasm of Body of Stomach in...
Phase Not Applicable
Enrollment 4190
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data (Through study completion, an average of 2 to 3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-02-21
Completion: 2035-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 4190 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academia Sinica, Taiwan
Collaborators: National Taiwan University Hospital
Principal Investigators:
  • Yu-Ju Chen, PhD (STUDY_DIRECTOR) - Distinguished Research Fellow
Contact Information
Study Contact:
Yu-Ju Chen, PhD
886-2-55728660
yujuchen@gate.sinica.edu.tw
Ming-Shiang Wu, M.D., PhD
National Taiwan University Hospital
Interventions
N/A
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, 100225 Taiwan
Eligibility Criteria
Inclusion Criteria: * lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer Exclusion Criteria: * other cancer types
Conditions Hormonal Receptors Positive, HER2 Negati...
Phase PHASE2
Enrollment 80
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, international, open-label phase II study. Based on inclusion/exclusion criteria, eligible pre and postmenopausal patients with newly diagnosed metastatic luminal hormone receptor-positive and HER2 negative breast cancer, will be prospectively treated with a standard combination of hormone therapy (Letrozole or Anastrozole) and Palbociclib. This combination will continue until progression. Treatment response will be evaluated every three months using clinical and radiological assessments (Revised RECIST guidelines). Patients will undergo serial liquid biopsies (blood tests) for plasma molecular fingerprinting by the Quantum Optics technology. This study will be the first program exploring the adjunction of the Quantum Optics technology on liquid biopsies to define individual 'molecular fingerprinting profiles' to predict the individual therapeutic effects of Palbociclib combined with Aromatase Inhibitors (AI) (plus ovarian function suppression (OFS) for pre/peri-menopausal patients) in luminal hormone receptor-positive and HER2 negative advanced breast cancer. Batteries of algorithmic tests will integrate the variables obtained by Quantum Optics (to evaluate the efficacy or not of the combination of Palbociclib + Aromatase Inhibitors (AI) ). This approach introduces the concept of singularity to break from the classic idea of "one size fits all".

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) — A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).

Primary Outcomes

  • Rate of Objective Clinical Response (From date of first treatment until the date of the first documented progression, assessed up to 2 years.)
  • Sensitivity and Specificity of prediction of the efficacy of the combination (palbociclib +AI). (From date of first treatment until the date of the first documented progression, assessed up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-20
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: International Cancer Research Group, United Arab Emirates
Collaborators: King Saud Medical City, Max-Planck-Institut für Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universität München (LMU), Garching, Germany, King Abdallah University for Science and Technology (KAUST), Thuwal, Saudi Arabia.
Principal Investigators:
  • M.R.K. BAHADOOR, MD, EMBA (STUDY_DIRECTOR) - International Cancer Research Group
Contact Information
Study Contact:
M.R.K. BAHADOOR, MD, EMBA
971586353489
mrkbahadoor@icrgrp.com
Farida DABOUZ, PhD
971564360008
farida.dabouz@icrgrp.com
Zoubir DERBOUZ, MD
EHS LCC Blida, Medical Oncology Center
Interventions
  • Drug: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) — A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
Study Locations (7 sites)
EHS LCC Blida, Medical Oncology Center, Blida, Algeria
University Hospital Sétif,, Sétif, Algeria
King Hussein Cancer Center (KHCC) - Amman, Amman, Jordan
King Saud Medical City - KSMC, Riyadh, Saudi Arabia
Medical Oncology Center- King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia
Medical Oncology Department- King Fahad Medical City (KFMC), Riyadh, Saudi Arabia
Oncology Center Department, King Faisal Specialist Hospital and Research Centre -KFSH & RC, Riyadh, Saudi Arabia
Eligibility Criteria
Inclusion Criteria: To be enrolled in the study, patients should meet the following inclusion criteria: 1. Written informed consent before beginning specific protocol procedures including expected cooperation of the patients for the treatment and follow-up must be obtained and documented according to the local regulatory requirements. 2. Postmenopausal women or pre/peri-menopausal women with Surgical oophorectomy (preferred) or Analogs of LHRH. 3. Performance status \< 3 (according to WHO criteria). 4. Histologically confirmed breast cancer (Luminal A or B). 5. Estrogen Receptor positive (ER \> 1%). 6. HER2 negative (score 0 or 1 by immunochemistry), FISH negative if IHC score 2. 7. Clinical stage IIIb \& IV. 8. Either: 1. Women with De novo advanced luminal HER2 negative advanced breast cancer without other prior systemic treatment for advanced disease. 2. Women with luminal HER2 negative advanced breast cancer either with secondary resistance (relapse after 2 years of adjuvant hormone therapy or within 12 months of completion of adjuvant HT) or sensitivity to adjuvant HT (relapse \> 12 months after completion of adjuvant HT). 9. Measurable or evaluable disease. 10. Hematology: * Neutrophil count ≥ 1.5 G/L, * Platelet count ≥ 100 G/L, * Leucocyte count \> 3.0 G/L, * Hb\> 9g/dl. 11. Hepatic function: * Total bilirubin ≤ 1.5 times the upper normal limit (UNL), * ASAT ≤ 2.5xUNL, * ALAT ≤ 2.5xUNL, * Alkaline phosphatase ≤ 2.5 times the upper normal limit (UNL). 12. Renal function: • Serum creatinine ≤1.5xUNL (and if Serum creatinine \>1.5xUNL, creatinine clearance ≥40 mL/min), 13. Metabolic function: • Serum calcium ≥ lower limit of normal. 14. Negative pregnancy test (urine or serum) within 7 days before registration for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment. 15. Patients with negative Human Immunodeficiency Virus (HIV) and/or Hepatitis B and/or Hepatitis C results. Exclusion Criteria: To be enrolled in the study, patients should meet the following exclusion criteria: 1. Male patients. 2. HER2 positive tumors or unknown HR/HER2 status. 3. Triple-negative Breast Cancer (ER\<1%). 4. Pregnant or breast-feeding women, or those who plan to become pregnant within 6 months post-treatment. 5. No willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months post-treatment. 6. Any form of breast cancer other than those described in the inclusion criteria, particularly inflammatory and/or loco-regional disease (stages I, II \& IIIa). 7. Non-evaluable tumor. 8. Bilateral breast cancer. 9. Patients with a history of other cancer, except in situ cervical cancer or baso-cellular skin cancer, considered cured. 10. Patient has another disease, which is deemed incompatible with the inclusion in the protocol. 11. Heart, kidney, medullary, respiratory or liver failure. * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) at baseline. * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease at baseline, * Acute urinary infection, ongoing hemorrhagic cystitis at baseline. 12. Uncontrolled diabetes. 13. Symptomatic or progressive disorder of the central nervous system (CNS) at baseline. 14. Patients with positive Human Immunodeficiency Virus (HIV) and/or Hepatitis B and/or Hepatitis C results. 15. Significant psychiatric abnormalities. 16. History of hypersensitivity to studied treatment or excipients. 17. Known previous or ongoing abuse of narcotic drug, other medication or alcohol. 18. Any investigational agent within 30 days before initiation of study treatment. 19. Patient unwilling or unable to comply with study requirements.
Conditions Breast Cancer
Phase PHASE2
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

NOAH study confirmed that trastuzumab combined with chemotherapy can significantly improve PCR compared with chemotherapy alone, and established the status of trastuzumab as a new adjuvant targeted therapy. The emergence of CDK4/6 inhibitors has brought hope to breast cancer patients resistant to endocrine therapy. studies have shown that pyrotinib maleate combined with CDK4/6 inhibitor can significantly inhibit the proliferation of HER2 positive breast cancer cell lines, reduce the activation of pAKT and pHER3, inhibit cell arrest in G0-G1 phase, and increase cell apoptosis. In the mouse model, pyrotinib maleate combined with CDK4/6 inhibitor exhibits higher anti-tumor activity than any anti-tumor drug alone. Moreover, the toxicity of the combined therapy does not increase compared with monotherapy. This provides a good preclinical model for the treatment of breast cancer by pyrotinib maleate combined with CDK4/6 inhibitor. In addition, NeoALTTO study、CALGB 40601 study、NSABP B-41 study confirmed that the clinical efficacy of lapatinib combined with trastuzumab combined chemotherapy was better than that of lapatinib or trastuzumab single target treatment group. Therefore, it is envisaged that the combination of pyrotinib maleate and dalpiciclib combined with letrozole on the basis of adding new trastuzumab to treat triple positive breast cancer will further improve the curative effect. In conclusion, we believe that pyrotinib maleate combined with trastuzumab, dalpiciclib and letrozole can provide better strategies for neoadjuvant therapy in patients with II-III three positive breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole — After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.

Primary Outcomes

  • Total pathological complete response (tpCR) (1 month to 5 years after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-02-10
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Principal Investigators:
  • Cai-Gang Liu, PHD (PRINCIPAL_INVESTIGATOR) - Shengjing Hospital
Contact Information
Study Contact:
Nan Niu, MD
+8618940256668
niunannancy@163.com
Nan Niu, MD
+8618940256668
niunannancy@163.com
Shengjing Hospital of China Medical University
Cai-Gang Liu, PHD
Shengjing Hospital of China Medical University
Interventions
  • Drug: Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole — After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
Study Locations (1 sites)
Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged≥18 years and ≤75 years meeting one of the following conditions; 1. Those previously receiving ovariectomy, or aged ≥60 years 2. Those aged \< 60 years who have had 12 consecutive months of amenorrhoea without any pathological or physical causes, and have postmenopausal E2 and follicle stimulating hormone (FSH) levels 3. Premenopausal or perimenopausal women who are willing to receive LHRH agonist treatment during the study period 2. Women who have breast cancer histopathologically confirmed by positive estrogen receptor (ER; \>10%), positive progesterone receptor (PR; \>1%), and positive human epidermal growth factor receptor 2 (HER2) according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline. ER, PR and HER2 will be assessed by immunohistochemistry (IHC) on harvested tissue. ER, PR and HER2 will be considered positive if the IHC result is positive (score 3+), or the IHC result is positive (2+) and in situ hybridization (ISH) amplification rate (≥2.0); 3. Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time; 4. Karnofsky Performance Status (KPS) Scale score ≥70; 5. The functional level of organs must meet the following requirements: a) Bone marrow function i) Absolute neutrophil count(ANC)≥1.5×109/L (no use of growth factor within 14 days) ii) Platelet count(PLT)≥100×109/L (no corrective treatment within 7 days) iii) Hemoglobin level(Hb)≥100 g/L (no corrective treatment within 7 days) b) Liver and kidney function i) Total bilirubin(TBIL)≤1.5 upper limit of normal value (ULN) ii) Alanine transaminase (ALT) and aspartate transaminase (AST) ≤3×ULN iii) Blood urea nitrogen (BUN) and creatinine ≤1.5×ULN and creatinine clearance≥50 mL/min (Cockcroft-Gault formula); c) Color Doppler echocardiography: Left ventricular ejection fraction ≥50% d) 12-lead electrocardiography: QTc interval ≤480 ms 6. Women who can undergo a biopsy; 7. Volunteers to participate in the study, provision of signed informed consent, good compliance and willingness to cooperate with follow-ups. Exclusion Criteria: 1. Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy); 2. Those who have received other anti-tumor drug treatments concurrently; 3. Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer; 4. Those who have stage IV breast cancer; 5. Those who have breast cancer not histopathologically confirmed; 6. Those who have other malignant tumors (with the exception of healed cervical carcinoma in situ) occurring in the past 5 years; 7. Those who have severe dysfunction of the heart, liver, kidney, and other major organs; 8. There are multiple factors that affect drug administration and absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction; 9. Those who have participated in other clinical drug trials in the past 4 weeks; 10. Those who are known to have a history of allergy to the component of study drugs; those who have a history of immunodeficiency, including positive detection of human immunodeficiency virus, hepatitis C virus, active hepatitis B or other acquired, congenital immunodeficiency diseases, or organ transplantation; 11. Those who had suffered from any heart disease, including arrhythmia which requires drug treatment or is of clinical significance; myocardial infarction; heart failure; and any other heart disease judged by the investigator as unsuitable for this trial; 12. Pregnant and lactating women; fertile women who provide positive results of baseline pregnancy test; women of childbearing age who are unwilling to take effective contraceptive measures during the whole study period; 13. If the accompanying diseases (including, but not limited to, severe hypertension, severe diabetes, and active infection, which cannot be controlled by drugs) that would be a potential hazard to participant's health, or affect the completion of the study as per investigator's judgement; 14. A clear history of neurological or psychiatric disorders, including epilepsy or dementia. Upon the suggestion of the investigators for other reasons
Conditions Primary Open-angle Glaucoma, Glaucoma
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. Composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. Studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency. Glaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. Two hypotheses have been proposed as a basis for this progressive damage: * the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and * the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. This latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied. Glycocalyx damage has rarely been studied in glaucoma. Yang et al. showed that the glycocalyx, present in Schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Glycocheck — Assessment of the sublingual microvascularization
  • Procedure: Ophthalmological examinations — Description : Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)

Primary Outcomes

  • Thickness of the Perfused boundary region (PBR) (Baseline day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-06
Completion: 2026-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Principal Investigators:
  • Cédric LAMIREL, MD (PRINCIPAL_INVESTIGATOR) - Hôpital Fondation A. de Rothschild
  • Georges AZAR, MD (STUDY_CHAIR) - Hôpital Fondation A. de Rothschild
Contact Information
Study Contact:
Amélie YAVCHITZ, MD
01 48 03 64 33
ayavchitz@for.paris
Cédric LAMIREL
clamirel@for.paris
Hôpital Fondation A. de Rothschild
Georges AZAR
gazar@for.paris
Hôpital Fondation A. de Rothschild
Interventions
  • Procedure: Glycocheck — Assessment of the sublingual microvascularization
  • Procedure: Ophthalmological examinations — Description : Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)
Study Locations (1 sites)
Hôpital Fondation A. de Rothschild, Paris, 75019 France
Eligibility Criteria
Inclusion Criteria: * Express consent to participate in the study * Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes * Only for control group: Absence optic nerve pathology (including primary open angle glaucoma) Exclusion Criteria: * Pregnant or breastfeeding woman * Sleep apnea * Renal insufficiency * Parkinson's disease * Alzheimer's disease * Antiphospholipid syndrome * Cancer for which treatment ended less than 2 years ago * Stroke less than 1 year ago * Myocardial infarction less than 1 year ago
Conditions Cancer, Cancer Diagnosis, Early Detectio...
Phase Not Applicable
Enrollment 25000
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types. Comprehensive molecular profiling will include somatic tumor testing (tissue and/or blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and/or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples. To maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research. Data collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Percent of patients participating in comprehensive molecular profiling (5 years)
  • Percent of patients referred for cascade genetic testing (5 years)
  • Percent of patients referred for molecularly targeted clinical trials (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-11-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 25000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Avera McKennan Hospital & University Health Center
Principal Investigators:
  • Rachel Elsey, PharmD (PRINCIPAL_INVESTIGATOR) - Avera Cancer Institute
Contact Information
Study Contact:
Rachel Elsey, PharmD
605-322-3225
Rachel.Elsey@avera.org
Avera Precision Research Team
888-422-1410
McK-MBX-PrecisionResearch@avera.org
Rachel Elsey, PharmD
605-322-3225
rachel.elsey@avera.org
Avera Cancer Institute - Marshall
Interventions
N/A
Study Locations (6 sites)
Avera Cancer Institute - Marshall, Marshall, Minnesota 56258 United States
Avera Cancer Institute - Aberdeen, Aberdeen, South Dakota 57401 United States
Avera Cancer Institute - Mitchell, Mitchell, South Dakota 57301 United States
Avera Cancer Institute - Pierre, Pierre, South Dakota 57501 United States
Avera Cancer Institute, Sioux Falls, South Dakota 57105 United States
Avera Cancer Institute - Yankton, Yankton, South Dakota 57078 United States
Eligibility Criteria
Inclusion Criteria: * Must be at least 18 years of age * Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer * Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation Exclusion Criteria: * Participants incapable of understanding the items listed in the consent form and process * Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements
Conditions Breast Cancer
Phase PHASE1, PHASE2
Enrollment 55
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. During the Phase IIa part of this study, the safe dose of pHLIP ICG will be used that makes it easy for the surgeon to see the tumor and the nearby tissues and structures that may contain cancer cells. This study is the first to test pHLIP ICG in people, and the first to test the use of pHLIP ICG with mpMRI and NIRF imaging in surgery for breast cancer.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: pHLIP® ICG NIRF imaging — Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery). In Phase I, we propose to investigate 4 different doses: Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40.

Primary Outcomes

  • Dose-limiting toxicity (DLT) (15 days post pHLIP® ICG injection)
  • Concordance between the absence of optical signal and histopathological confirmation of absence of malignancy. (Phase II) (1 year)
  • Visualization of a lesion with pHLIP® ICG (Phase II) (up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-11-19
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Stryker Instruments, pHLIP Inc.
Principal Investigators:
  • Giacomo Montagna, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Giacomo Montagna, MD
646-888-6891
montagng@mskcc.org
Monica Morrow, MD
646-888-5350
Giacomo Montagna, MD
646-888-6891
Memorial Sloan Kettering Bergen (All Protocol Activities)
Interventions
  • Diagnostic Test: pHLIP® ICG NIRF imaging — Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery). In Phase I, we propose to investigate 4 different doses: Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40.
Study Locations (2 sites)
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or greater * Biopsy proven primary breast malignancy (BI-RADS 6) * Tumor stage Tis, T1 and T2, lesion size \> 1 cm * Primary surgical treatment with breast conservation * No previous treatment * ECOG performance of 0-2 Exclusion Criteria: * Life expectancy \< 3 months * Pregnancy or lactation * Known metastatic liver disease, hepatic neoplasms (benign and malignant), biliary atresia, chronic liver disease (CLD) and cirrhosis. * Known moderate hepatic impairment (in phase I, and in phase IIa dependent on safety profile established in phase I) * Known hypersensitivity to indocyanine green. * Individuals with impaired-decision making capacity
Conditions Hypertension
Phase NA
Enrollment 96
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure is a leading risk factor for cardiovascular disease. Traditionally, one of the ways to treat or prevent high blood pressure is to prescribe aerobic exercise training (i.e. brisk walking). Stretching may also be effective because it may cause changes in blood vessel stiffness and therefore reduce resistance to blood flow. The study will assess a group of individuals (i.e. 96) participating in a supervised stretching or walking program five days per week for six months to determine whether stretching is superior for reducing blood pressure. This research will contribute to recommendations about the most effective exercise programs for reducing blood pressure and risk of cardiovascular disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Stretching exercise — Stretching (30-45 minutes, 5 days per week, 6 months)
  • Other: Walking exercise — Walking (30-45 minutes, 5 days per week, 6 months)

Primary Outcomes

  • Night time systolic and diastolic blood pressure (Change from baseline night time blood pressure at 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-28
Completion: 2026-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Saskatchewan
Collaborators: Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Philip Chilibeck, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Saskatchewan
Contact Information
Study Contact:
Philip Chilibeck, Ph.D.
306-966-1072
phil.chilibeck@usask.ca
John Ko, M.Sc.
306-966-1082
jongbum.ko@usask.ca
John Ko, M.Sc.
306-966-1186
jongbum.ko@usask.ca
University of Saskatchewan
Interventions
  • Other: Stretching exercise — Stretching (30-45 minutes, 5 days per week, 6 months)
  • Other: Walking exercise — Walking (30-45 minutes, 5 days per week, 6 months)
Study Locations (1 sites)
University of Saskatchewan, Saskatoon, Saskatchewan S7N5B2 Canada
Eligibility Criteria
Inclusion Criteria: * Systolic blood pressure between 130 and 159 mmHg OR diastolic blood pressure between 85 and 99 mmHg * Able to walk unaided for 30 minutes * Can safely perform exercises as determined by the Get Active Questionnaire Exclusion Criteria: * Not on blood pressure medication unless it has been a stable dose for 6 months and target blood pressure has not been achieved (i.e. below 140/90 mmHg) * Smoking * Already performing 150 minutes or more moderate to vigorous physical activity per week * Already involved in a flexibility-training program (e.g. Yoga or Pilates) * Pregnant or lactating or planning to become pregnant during the study
Conditions Breast Cancer, Mastectomy, Pain, Chronic...
Phase NA
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In 230 patients undergoing mastectomy, the investigators will compare opioid-free anesthesia (OFA) versus conventional opioid-based anesthesia in terms of chronic pain. The enrolled patients will be randomly assigned into two groups with 1:1 ratio. Chronic pain will be evaluated at 1 year after mastectomy based on the Breast Cancer Pain Questionnaire (BCPQ). Baseline pain sensitivity test and psychologic evaluation will be done before operation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Procedure: Opioid-free anesthesia — OFA group will be sedated using dexmedetomidine and lidocaine.
  • Procedure: Conventional opioid-based anesthesia — Conventional opioid-based anesthesia group will be sedated using remi-fentanyl

Primary Outcomes

  • chronic breast pain at 1 year after mastectomy (1 year after mastectomy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-12-16
Completion: 2027-10-31
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gangnam Severance Hospital
Principal Investigators:
  • Sung Gwe G Ahn, M.D.,Ph.D. (PRINCIPAL_INVESTIGATOR) - Gangnam Severance Hospital
Contact Information
Study Contact:
Sung Gwe Ahn, M.D.,Ph.D.
82220194402
asg2004@yuhs.ac
Soong June Bae, M.D.
82220193370
mission815815@yuhs.ac
Sung Gwe Ahn, MD, PhD
82-2-2019-3370
asg2004@yuhs.ac
Gangnam Severance Hospital
Interventions
  • Procedure: Opioid-free anesthesia — OFA group will be sedated using dexmedetomidine and lidocaine.
  • Procedure: Conventional opioid-based anesthesia — Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
Study Locations (1 sites)
Gangnam Severance Hospital, Seoul, 135270 South Korea
Eligibility Criteria
Inclusion Criteria: * All of patients will undergo mastectomy with or without immediate breast reconstruction. Exclusion Criteria: * Previous history of breast surgery * Allergy to drug * Other cancer history * Underlying psychologic disorder * Patients with chronic pain requiring pain killers * Baseline SpO2 \<95% * Left ventricular EF \<40% * Bradycardia as HR \<50 bpm * BMI \>35kg/m2 * Pregnant woman
Conditions PIK3CA Mutation, Solid Tumor, Adult, HER...
Phase PHASE1
Enrollment 930
Locations 37 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RLY-2608 — RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
  • Drug: Fulvestrant — 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
  • Drug: Palbociclib 125mg — 125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
  • Drug: Ribociclib 400mg — 400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
  • Drug: Ribociclib 600mg — 600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
  • Drug: PF-07220060 100mg — PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
  • Drug: PF-07220060 300 mg — PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.

Primary Outcomes

  • Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 as a single agent (Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months)
  • Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrant (Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months)
  • Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrant (Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months)
  • Number of patients with adverse events and serious adverse events of RLY-2608 as a single agent (Every cycle (4-week cycles) until study discontinuation, approximately 24 months)
  • Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrant (Every cycle (4-week cycles) until study discontinuation, approximately 24 months)
  • Number of patients with adverse events and serious adverse events of RLY-2608 in combination with fulvestrant and a CDK 4/6 inhibitor (palbociclib, ribociclib), and in combination with CDK4 inhibitor (PF-07220060) and fulvestrant (Every cycle (4-week cycles) until study discontinuation, approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-12-08
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 930 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Relay Therapeutics, Inc.
Contact Information
Study Contact:
Relay Therapeutics Inc
617-322-0731
ClinicalTrials@relaytx.com
Interventions
  • Drug: RLY-2608 — RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
  • Drug: Fulvestrant — 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
  • Drug: Palbociclib 125mg — 125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
  • Drug: Ribociclib 400mg — 400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
  • Drug: Ribociclib 600mg — 600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study Locations (37 sites)
The University of Arizona Cancer Center, Tucson, Arizona 85724 United States
University of California-San Diego, San Diego, California 90293 United States
HealthONE, Denver, Colorado 80218 United States
Yale University, New Haven, Connecticut 06510 United States
Florida Cancer Specialists, Orlando, Florida 32827 United States
Boca Raton Clinical Research (BRCR) Global, Plantation, Florida 33322 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Community Health Network, Indianapolis, Indiana 46250 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Eligibility Criteria
Key Inclusion Criteria Patient has ECOG performance status of 0-1 One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment Other potentially oncogenic PIK3CA mutations may be considered but must be approved by the Sponsor prior to enrollment. Part 1 \[Escalation\] - Ability to provide archived tumor tissue or be willing to undergo pretreatment tumor biopsy to assess PIK3CA status retrospectively Part 2 \[Expansion\] - Submit tumor tissue prior to study drug initiation for determination of PIK3CA mutation retrospectively. Key Inclusion for RLY-2608 Single Agent Arm * \[For Part 1: Escalation\]: Evaluable disease per RECIST v1.1 * \[For Part 2: Expansion\]: Measurable disease per RECIST v1.1 * Disease that is refractory to standard therapy, intolerant to standard therapy, or has declined standard therapy. * Part 1- histologically or cytologically confirmed diagnosis of unresectable or metastatic solid tumor * Part 2 - Unresectable or metastatic solid tumor with PIK3CA mutation(s) and one of the following tumor types: Group 1: clear cell ovarian cancer Group 2: head and neck squamous cell carcinoma Group 3: cervical cancer Group 4: other solid tumors, excluding colorectal, clear cell ovarian, head and neck squamous cell, and cervical cancers Group 5: unresectable or metastatic solid tumors with PIK3CA double mutations In addition, the SRC (with Sponsor approval) may choose to open additional group(s) of 20 participants to study the clinical activity, safety, and PK/PD with other specified solid tumor types. Key Inclusion for Combination Arms: * Doublet combination arms \[Part 1 and Part 2\]: Evaluable disease per RECIST v1.1 * Triplet combination arms: * \[Part 1 and Part 2 Dose Expansion, Group 1\]: Evaluable disease per RECIST. * \[Part 2 Dose Expansion, Group 2\]: Measurable disease per RECIST. Bone-only lytic or lytic/blastic disease with at least 1 measurable soft-tissue component per RECIST may be eligible. * \[For Part 1 and Part 2\]: Male or female with histologically or cytologically confirmed diagnosis of HR+, HER2- unresectable or metastatic breast cancer that is not amenable to curative therapy. Females may be postmenopausal, premenopausal, or perimenopausal. Premenopausal or perimenopausal females must have a histologically or cytologically confirmed diagnosis of HR+ HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy and must have initiated treatment with a gonadotropin-releasing hormone (GnRH) agonist at least 4 weeks prior to start of study drug with continuation of GnRH agonist for the duration of study treatment (GnRH agonist recommended for males). * Had previous treatment for breast cancer with: \[Does not apply to triplet combination arms, Part 2 Dose Expansion, Group 2\]: 1. ≤1 line of chemotherapy in the metastatic setting 2. ≥1 CDK4/6 inhibitor in either the adjuvant and/or metastatic setting 3. ≥1 antiestrogen therapy in either adjuvant and/or metastatic setting, including, but not limited to, selective estrogen-receptor degraders (eg, fulvestrant), selective estrogen receptor modulators (eg, tamoxifen), and aromatase inhibitors (AI) (letrozole, anastrozole, exemestane), and 4. ≥1 PARP inhibitor, if appropriate, if documented germline BRCA1/2 mutation Note: Systemic local, loco-regional, or adjuvant treatment with chemotherapy and PARP inhibitors is not to be included in enumeration or previous treatment \[For double combination arm; Part 2 Dose Expansion, Group 2\]: Received prior treatment with a PI3Kα, AKT, or mTOR inhibitor and discontinued the inhibitor due to intolerance and not disease progression, where intolerance is defined as treatment discontinuation due to treatment related AE (eg. hyperglycemia, rash, diarrhea, stomatitis) other than severe hypersensitivity reaction and/or life-threatening reactions, such as anaphylaxis and Stevens-Johnson syndrome. \[For triple combination arms; Part 1 dose escalation\]: Participants who had previous treatment for breast cancer with PI3Kα, AKT, mTOR inhibitors and discontiuned due to participant/physician decision, intolerance, or disease progression will be considered. \[For triple combination arms, Part 2 Dose Expansion, Group 2\]: Participants must be intolerant to or have declined standard therapy for locally advanced or metastatic HR+/HER2- PIK3CA-mutated breast cancer. Prior endocrine therapy and CDK4/6inhibitors are allowed as follows: 1. Participants must have progressed during (neo)adjuvant endocrine therapy or within12 months of completing (neo)adjuvant endocrine therapy with an AI or tamoxifen. 2. If a CDK4/6 inhibitor was included as part of (neo)adjuvant therapy, disease must have recurred/progressed \>12 months after completion of the CDK4/6 inhibitor portion of (neo)adjuvant therapy Key Exclusion Criteria Prior treatment with: 1. PI3Kα, AKT, or mTOR inhibitors (all arms except for doublet RLY-2608 + fulvestrant arm, Part 2, Group 2; and triplet combinations, Part 1 dose escalation). 2. Immune checkpoint inhibitors. 3. Triplet combinations RLY-2608 + CDK4 or CDK4/6 inhibitor + fulvestrant, Part 2 expansion, Group 2 only: i. Prior systemic chemotherapy or antibody drug conjugate for locally advanced or metastatic disease. ii. Prior CDK2, CDK4, or CDK4/6 inhibitor as treatment for locally advanced or metastatic disease. iii. Prior treatment with fulvestrant or any selective ER degrader, with the exception of patients who have received fulvestrant or any selective ER degrader as part of neoadjuvant therapy only and with treatment duration ≤6 months. Type 1 or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥140 mg/dL and glycosylated hemoglobin (HbA1c) ≥7.0%. History of allergy or hypersensitivity to any components or excipients of PI3K inhibitors. For combination arms only: allergy or hypersensitivity to any components or excipients of fulvestrant, palbociclib, ribociclib, and/or PF-07220060 as appropriate for the combination. Past medical history of or ongoing ILD, or pneumonitis requiring intervention. Participants with past history of resolved Grade 1 pneumonitis may be considered, except in triple combination arms. The following cardiac criteria: * Mean resting corrected QT interval (QTc) \>460 msec * For triple combination arm with ribociclib: Mean QTcF ≥450 msec (this is what we confirmed is shown in the redacted version of the protocol. CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms
Conditions Genetic Testing, Breast Cancer, Ovarian ...
Phase NA
Enrollment 1020
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Video Education — Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
  • Behavioral: Genetic Counseling — Standard genetic counseling

Primary Outcomes

  • Video Education Acceptability (Qualitative Interview Study) (3 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-04
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1020 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI)
Principal Investigators:
  • Huma Q. Rana, MD., MPH (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Huma Q. Rana, MD. MPH
617) 632-6292
humaQ_rana@dfci.harvard.edu
Huma Q Rana, MD
617-632-6292
HumaQ_Rana@DFCI.HARVARD.EDU
Dana Farber Cancer Institute
Huma Q Rana, MD
Dana Farber Cancer Institute
Interventions
  • Behavioral: Video Education — Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
  • Behavioral: Genetic Counseling — Standard genetic counseling
Study Locations (1 sites)
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma * Ability to understand spoken or written English or Spanish in a healthcare context * Ability to understand and the willingness to sign a written informed consent document * Black or Latinx (qualitative assessment study only) Exclusion Criteria: * Prior cancer genetic testing * Prior germline genetic testing * Active hematologic malignancy (e.g. chronic lymphocytic leukemia) * Currently pregnant * Currently incarcerated